Amyloid beta-Peptides

"Amyloid beta-Peptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Peptides generated from AMYLOID BETA-PEPTIDES PRECURSOR. An amyloid fibrillar form of these peptides is the major component of amyloid plaques found in individuals with Alzheimer's disease and in aged individuals with trisomy 21 (DOWN SYNDROME). The peptide is found predominantly in the nervous system, but there have been reports of its presence in non-neural tissue.

Descriptor ID	D016229
MeSH Number(s)	D12.644.024 D12.776.049.407.249.500 D12.776.543.039.500
Concept/Terms	Amyloid beta-Peptides Amyloid beta-Peptides Amyloid beta Peptides beta-Peptides, Amyloid Alzheimer's ABP ABP, Alzheimer's Alzheimer ABP Alzheimers ABP Alzheimer's Amyloid Fibril Protein Amyloid AD-AP AD-AP, Amyloid Amyloid AD AP beta-Amyloid Protein Protein, beta-Amyloid beta Amyloid Protein Amyloid beta-Protein Amyloid beta Protein beta-Protein, Amyloid Amyloid beta-Proteins Amyloid beta Proteins beta-Proteins, Amyloid Amyloid Fibril Protein, Alzheimer's Amyloid Protein A4 Protein A4, Amyloid Alzheimer beta-Protein Alzheimer beta Protein beta-Protein, Alzheimer Amyloid beta-Peptide Amyloid beta Peptide beta-Peptide, Amyloid

Below are MeSH descriptors whose meaning is more general than "Amyloid beta-Peptides".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Peptides [D12.644]
Amyloid beta-Peptides [D12.644.024]
Proteins [D12.776]
Amyloid [D12.776.049]
Amyloidogenic Proteins [D12.776.049.407]
Amyloid beta-Protein Precursor [D12.776.049.407.249]
Amyloid beta-Peptides [D12.776.049.407.249.500]
Membrane Proteins [D12.776.543]
Amyloid beta-Protein Precursor [D12.776.543.039]
Amyloid beta-Peptides [D12.776.543.039.500]

Below are MeSH descriptors whose meaning is related to "Amyloid beta-Peptides".

Below are MeSH descriptors whose meaning is more specific than "Amyloid beta-Peptides".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Amyloid beta-Peptides" by people in this website by year, and whether "Amyloid beta-Peptides" was a major or minor topic of these publications.

Bar chart showing 259 publications over 25 distinct years, with a maximum of 28 publications in 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1998	1	0	1
2001	3	0	3
2002	3	1	4
2003	1	1	2
2005	6	1	7
2006	4	2	6
2007	3	3	6
2008	4	0	4
2009	5	7	12
2010	8	6	14
2011	9	3	12
2012	4	4	8
2013	3	3	6
2014	5	4	9
2015	6	1	7
2016	5	3	8
2017	4	4	8
2018	4	6	10
2019	12	11	23
2020	8	11	19
2021	2	11	13
2022	3	22	25
2023	1	16	17
2024	14	14	28
2025	2	5	7

Below are the most recent publications written about "Amyloid beta-Peptides" by people in Profiles.

Villacampa N, Sarlus H, Martorell P, Bhalla K, Castro-Gomez S, Vieira-Saecker A, Slutzkin I, H?ndler K, Venegas C, McManus R, Ulas T, Beyer M, Segal E, Heneka MT. Proliferating Microglia Exhibit Unique Transcriptional and Functional Alterations in Alzheimer's Disease. ASN Neuro. 2025; 17(1):2506406.

View in: PubMed
Wang G, Li Y, Xiong C, Cao Y, Schindler SE, McDade E, Blennow K, Hansson O, Dage JL, Jack CR, Teunissen CE, Shaw LM, Zetterberg H, Ibanez L, Timsina J, Carlos C, Bateman RJ. The CentiMarker project: Standardizing quantitative Alzheimer's disease fluid biomarkers for biologic interpretation. Alzheimers Dement. 2025 Apr; 21(4):e14587.

View in: PubMed
Leuzy A, Bollack A, Pellegrino D, Teunissen CE, La Joie R, Rabinovici GD, Franzmeier N, Johnson K, Barkhof F, Shaw LM, Arkhipenko A, Schindler SE, Honig LS, Moscoso Rial A, Sch?ll M, Zetterberg H, Blennow K, Hansson O, Farrar G. Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease. Alzheimers Dement. 2025 Mar; 21(3):e14528.

View in: PubMed
Kuhn E, Klinger HM, Amariglio RE, Wagner M, Jessen F, D?zel E, Heneka MT, Ch?telat G, Rentz DM, Sperling RA, Ebenau JL, Butterbrod E, Van Der Flier WM, Sikkes SAM, Teunnissen CE, Van Harten AC, Van De Giessen EM, Rami L, Tort A, S?nchez Benavides G, Gifford KA, Van Hulle C, Buckley RF. SCD-plus features and AD biomarkers in cognitively unimpaired samples: A meta-analytic approach for nine cohort studies. Alzheimers Dement. 2025 May; 21(5):e14307.

View in: PubMed
Ashton NJ, Keshavan A, Brum WS, Andreasson U, Arslan B, Droescher M, Barghorn S, Vanbrabant J, Lambrechts C, Van Loo M, Stoops E, Iyengar S, Ji H, Xu X, Forrest-Hay A, Zhang B, Luo Y, Jeromin A, Vandijck M, Bastard NL, Kolb H, Triana-Baltzer G, Bali D, Janelidze S, Yang SY, Demos C, Romero D, Sigal G, Wohlstadter J, Malyavantham K, Khare M, Jethwa A, Stoeckl L, Gobom J, Kac PR, Gonzalez-Ortiz F, Montoliu-Gaya L, Hansson O, Rissman RA, Carrillo MC, Shaw LM, Blennow K, Schott JM, Zetterberg H. The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study. Alzheimers Dement. 2025 Feb; 21(2):e14508.

View in: PubMed
McManus RM, Komes MP, Griep A, Santarelli F, Schwartz S, Ram?n Perea J, Schlachetzki JCM, Bouvier DS, Khalil MA, Lauterbach MA, Heinemann L, Schl?ter T, Pour MS, Lovotti M, Stahl R, Duthie F, Rodr?guez-Alc?zar JF, Schmidt SV, Spitzer J, Noori P, Maillo A, Boettcher A, Herron B, McConville J, Gomez-Cabrero D, Tegn?r J, Glass CK, Hiller K, Latz E, Heneka MT. NLRP3-mediated glutaminolysis controls microglial phagocytosis to promote Alzheimer's disease progression. Immunity. 2025 Feb 11; 58(2):326-343.e11.

View in: PubMed
Schneider LS, Freiesleben SD, van Breukelen G, Wang X, Brosseron F, Heneka MT, Teipel S, Kleineidam L, Stark M, Roy-Kluth N, Wagner M, Spottke A, Schmid M, Roeske S, Laske C, Munk MH, Perneczky R, Rauchmann BS, Buerger K, Janowitz D, D?zel E, Glanz W, Jessen F, Rostamzadeh A, Wiltfang J, Bartels C, Kilimann I, Schneider A, Fliessbach K, Priller J, Spruth EJ, Hellmann-Regen J, Peters O. Linking higher amyloid beta 1-38 (A?(1-38)) levels to reduced Alzheimer's disease progression risk. Alzheimers Dement. 2025 Feb; 21(2):e14545.

View in: PubMed
Weiner MW, Kanoria S, Miller MJ, Aisen PS, Beckett LA, Conti C, Diaz A, Flenniken D, Green RC, Harvey DJ, Jack CR, Jagust W, Lee EB, Morris JC, Nho K, Nosheny R, Okonkwo OC, Perrin RJ, Petersen RC, Rivera-Mindt M, Saykin AJ, Shaw LM, Toga AW, Tosun D, Veitch DP. Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials. Alzheimers Dement. 2025 Jan; 21(1):e14321.

View in: PubMed
Schrempel S, Kottwitz AK, Piechotta A, Gnoth K, B?schgens L, Hartlage-R?bsamen M, Morawski M, Schenk M, Kleinschmidt M, Serrano GE, Beach TG, Rostagno A, Ghiso J, Heneka MT, Walter J, Wirths O, Schilling S, Ro?ner S. Identification of isoAsp7-A? as a major A? variant in Alzheimer's disease, dementia with Lewy bodies and vascular dementia. Acta Neuropathol. 2024 Dec 03; 148(1):78.

View in: PubMed
Stark M, Wagner M, Kuhn E, B?rger K, D?zel E, Hellmann-Regen J, Heneka MT, Laske C, Perneczky R, Peters O, Priller J, Schmid M, Schneider A, Spottke A, Teipel S, Wiltfang J, Jessen F, Kleineidam L. Clinical Manifestations. Alzheimers Dement. 2024 Dec; 20 Suppl 3:e091377.

View in: PubMed

People

Explore

Similar Concepts

Top Journals